(Q37096700)

18 August 2017

1 reference

title

Active surveillance for early-stage prostate cancer: review of the current literature (English)

1 reference

18 August 2017

1 reference

Matthew R Cooperberg

2

0 references

Philip W. Kantoff

object named as

Philip W Kantoff

11

0 references

Lars Holmberg

8

object named as

Lars Holmberg

1 reference

18 August 2017

6

Laurence H Klotz

1 reference

18 August 2017

Marc A Dall'Era

1

1 reference

18 August 2017

June M Chan

3

1 reference

18 August 2017

Benjamin J Davies

4

1 reference

18 August 2017

Peter C Albertsen

5

1 reference

18 August 2017

Christopher A Warlick

7

1 reference

18 August 2017

Donald E Bailey

9

1 reference

18 August 2017

Meredith E Wallace

10

1 reference

18 August 2017

Peter R Carroll

12

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

112

1 reference

18 August 2017

1650-1659

1 reference

18 August 2017

8

1 reference

Active surveillance with selective delayed intervention for favorable risk prostate cancer.

18 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Geographic pathology of latent prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Natural History of Early, Localized Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Evaluation of nitrous oxide anesthesia for endoscopic and laparoscopic urological applications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Incidence of prostatic carcinoma in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Cancer burden in the year 2000. The global picture

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Counterpoint: robot-assisted laparoscopic prostatectomy: perhaps the surgical gold standard for prostate cancer care

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The independent impact of extended pattern biopsy on prostate cancer stage migration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Increased accuracy of biopsy Gleason score obtained by extended needle biopsy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Natural history of changes in prostate specific antigen in early stage prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

20-year outcomes following conservative management of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Delayed versus immediate surgical intervention and prostate cancer outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Counseling Men With Prostate Cancer: A Nomogram for Predicting the Presence of Small, Moderately Differentiated, Confined Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Prostate biopsy tumor extent but not location predicts recurrence after radical prostatectomy: results from CaPSURE.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Urologic imaging for localized prostate cancer in 2007.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Early outcomes of active surveillance for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Watching, waiting and uncertainty in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Living with untreated localized prostate cancer: a qualitative analysis of patient narratives.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Uncertainty and Quality of Life of Older Men Who Undergo Watchful Waiting for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Is 'watchful waiting' a real choice for men with prostate cancer? A qualitative study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Uncertainty intervention for watchful waiting in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Defining aggressive prostate cancer using a 12-gene model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23373

7 January 2021

Identifiers

DOI

10.1002/CNCR.23373

1 reference

18 August 2017

1 reference